Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study

Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study

Introduction: The phase 3 DUPLEX trial is evaluating sparsentan, a novel, nonimmunosuppressive, single-molecule dual endothelin angiotensin receptor antagonist, in patients with focal segmental glomerulosclerosis (FSGS). Methods: DUPLEX (NCT03493685) is a global, multicenter, randomized, double-blin...

Full description

Saved in:

Bibliographic Details
Main Authors:	Howard Trachtman, Jai Radhakrishnan, Michelle N. Rheault, Charles E. Alpers, Jonathan Barratt, Hiddo J.L. Heerspink, Irene L. Noronha, Vlado Perkovic, Brad Rovin, Hernán Trimarchi, Muh Geot Wong, Alex Mercer, Jula Inrig, William Rote, Ed Murphy, Patricia W. Bedard, Sandra Roth, Stewart Bieler, Radko Komers
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney International Reports
Subjects:	dual endothelin angiotensin receptor antagonist focal segmental glomerulosclerosis pediatric race randomized controlled clinical trial sparsentan
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924000421
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Real-world assessment of sparsentan’s drug safety framework
by: Wenjing Fu, et al.
Published: (2025-12-01)

WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN24-774 PRELIMINARY FINDINGS FROM THE PHASE 2 EPPIK STUDY OF SPARSENTAN IN PEDIATRIC PATIENTS WITH SELECTED PROTEINURIC GLOMERULAR DISEASES
by: Radko Komers, et al.
Published: (2024-04-01)

Intravenous Rituximab in Severe Refractory Primary Focal Segmental Glomerulosclerosis
by: Wee Leng Gan, et al.
Published: (2018-10-01)

Intravenous Rituximab in Severe Refractory Primary Focal Segmental Glomerulosclerosis
by: Wee Leng Gan, et al.
Published: (2018-10-01)

Proteinuria and Progression of Renal Damage: The Main Pathogenetic Mechanisms and Pharmacological Approach
by: Elisa Longhitano, et al.
Published: (2024-11-01)

Focal segmental glomerulosclerosis: current status of the problem
by: I. T. Murkamilov, et al.
Published: (2020-01-01)

Assessment of podocyte detachment as a pivotal step in the development of focal segmental glomerulosclerosis
by: Ikbal Ahmed Abdo Elkholy, et al.
Published: (2024-11-01)

Advances in Focal Segmental Glomerulosclerosis Treatment From the Perspective of the Newest Mechanisms of Podocyte Injury
by: Zhu Y, et al.
Published: (2025-02-01)

From Gene to Clinic: The Role of APOL1 in Focal Segmental Glomerulosclerosis
by: Charlotte Delrue, et al.
Published: (2025-02-01)

Pathogenesis of Focal Segmental Glomerulosclerosis and Minimal Change Disease: Insights from Glomerular Proteomics
by: Yuriy Maslyennikov, et al.
Published: (2025-03-01)

Primary biliary cholangitis with focal segmental glomerulosclerosis:a case report with a literature review
by: Sun Jing, et al.
Published: (2021-01-01)

IgA Nephropathy Associated with IgA Vasculitis Coexisting with Focal Segmental Glomerulosclerosis Tip Variant
by: Zitlali Guadalupe Paulín Zepeda, et al.
Published: (2023-07-01)

Protective Role of the Podocyte IL-15 / STAT5 Pathway in Focal Segmental Glomerulosclerosis
by: Aïssata Niasse, et al.
Published: (2024-04-01)

Microarray analysis of the effects of Acthar Gel versus methylprednisolone in a model of focal segmental glomerulosclerosis in female rats
by: Kyle Hayes, et al.
Published: (2025-04-01)

Steroid‐Induced Psychosis in a Child With Nephrotic Syndrome Secondary to Focal Segmental Glomerulosclerosis: A Case Report
by: Sushan Pokharel, et al.
Published: (2024-12-01)

Predictive Ability of Interstitial Fibrosis and Tubular Atrophy Scoring in Determining the Severity of Diabetic Kidney Disease: A Cross-sectional Study
by: Shamantha Gopichand, et al.
Published: (2024-11-01)

Efficacy and safety of nine immunosuppressive agents for primary focal segmental glomerulosclerosis in adults: a pairwise and network meta-analysis
by: Yan Zhu, et al.
Published: (2024-12-01)

Glomerulosclerosis is a prognostic risk factor in patients with membranous nephropathy and non-nephrotic proteinuria
by: Jing Sun, et al.
Published: (2023-12-01)

Incidence and risk factors for recurrent focal segmental glomerulosclerosis after kidney transplantation: a meta-analysis
by: Jiang Bai, et al.
Published: (2023-12-01)

WCN24-773 SPARSENTAN AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY: PRELIMINARY FINDINGS FROM THE SPARTAN TRIAL
by: Chee Kay Cheung, et al.
Published: (2024-04-01)

A polymeric dexamethasone prodrug attenuates focal segmental glomerulosclerosis (FSGS) in an Adriamycin-induced mouse model with minimal glucocorticoid side effects
by: Haochen Jiang, et al.
Published: (2025-03-01)

Co-occurrence of Charcot-Marie-Tooth disease type 1 and glomerulosclerosis in a patient with a de novo INF2 variant
by: Yin Ding, et al.
Published: (2024-11-01)

GNCnn: A QuPath extension for glomerulosclerosis and glomerulonephritis characterization based on deep learning
by: Israel Mateos-Aparicio-Ruiz, et al.
Published: (2025-01-01)

Refining the adriamycin‐induced focal segmental glomerulosclerosis mouse model to improve reproducibility and animal welfare
by: Haochen Jiang, et al.
Published: (2025-05-01)

WCN24-752 CONCOMITANT SPARSENTAN AND SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2is) IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN) IN THE PROTECT OPEN-LABEL EXTENSION (OLE)
by: Radko Komers, et al.
Published: (2024-04-01)

Value of urinary CD80 in differentiating minimal change disease from focal segmental glomerulosclerosis
by: Phuong Anh Le-Thy, et al.
Published: (2024-06-01)

Opportunities and challenges in the treatment of IgA nephropathy
by: Yang Yang, et al.
Published: (2025-07-01)

Efficacy and safety of agents for IgA nephropathy: a network meta-analysis of randomized controlled trials
by: Bo Chen, et al.
Published: (2025-06-01)

Global glomerulosclerosis proportions predict nephropathy progression in IgA nephropathy: a multicenter retrospective analysis with propensity score matching
by: Wenli Zou, et al.
Published: (2025-12-01)

WCN24-1132 ACTION3 – Phase 3 study of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS)
by: Jonathon Barratt, et al.
Published: (2024-04-01)

A Prospective Study on Complement Activation Distinguishes Focal Segmental Glomerulosclerosis from Minimal Change Disease
by: Alexandra Cambier, et al.
Published: (2024-03-01)

Morphometric analysis of glomeruli, clinical features and outcome in obese and non-obese focal segmental glomerulosclerosis patients
by: Jordanova Elena, et al.
Published: (2021-01-01)

A clinical case of using therapeutic plasma exchange for the treatment of recurrent focal segmental glomerulosclerosis in a child after kidney transplantation
by: I. A. Miloserdov, et al.
Published: (2021-07-01)

Clinicopathological and prognostic study of idiopathic membranous nephropathy with tip or non-tip variant focal segmental glomerulosclerosis: a single-center cohort study
by: Shungang Xu, et al.
Published: (2025-12-01)

Coenzyme Q10 supplementation in adult-onset focal segmental glomerulosclerosis caused by the Chinese common pathogenic variant c.737G > A (p.Ser246Asn) in the COQ8B gene
by: Shi Jin, et al.
Published: (2025-12-01)

WCN25-1898 IMPLICATIONS OF PROTEINURIA REMISSION ON ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) TRAJECTORY IN PATIENTS (Pts) WITH IgA NEPHROPATHY (IgAN) IN PROTECT
by: Bruce Hendry, et al.
Published: (2025-02-01)

Primary focal segmental glomerulosclerosis in second trimester pregnancy presenting as rapidly progressive renal failure: diagnostic and therapeutic challenges: a case report
by: Adane Petros, et al.
Published: (2025-07-01)

Glomerular parietal epithelial expression of CD44 in minimal change nephrotic syndrome and primary focal segmental glomerulosclerosis: A clinico-pathological study
by: Nithin E Paul, et al.
Published: (2023-07-01)

Population risk predictors of major adverse kidney events attributed to focal segmental glomerulosclerosis from the CURE-CKD registry
by: Susanne B. Nicholas, et al.
Published: (2025-07-01)